EUVIMEDEUVIMED entdecken
Übersichtsarbeit

B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice

Matthew R Peery, Hailey Hill, Amanda Sharps, Aarti Zaver, Donald C Moore iD

Annals of Pharmacotherapy · 2025

DOI: 10.1177/10600280241282115 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Matthew R Peery und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Virginia Commonwealth University Medical Center, VCU Health, Richmond, VA, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, B-Cell Maturation Antigen, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To review the pharmacology, efficacy, safety, dosing and administration, and relevance to patient care and clinical practice of B-cell maturation antigen (BCMA) directed immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAb), for the management of relapsed/refractory multiple myeloma (RRMM). Data Sources: A literature review of PubMed (1966 to July 2024) was conducted using the keywords idecabtagene vicleucel , ciltacabtagene autoleucel, teclistamab, elranatamab , and multiple myeloma . Data was also obtained from unpublished meeting abstracts and prescribing information. Study Selection and Data Extraction: All relevant published articles, unpublished abstracts, and prescribing information on anti-BCMA immunotherapies for the treatment of RRMM were reviewed. Data Synthesis: Idecabtagene vicleucel and ciltacabtagene autoleucel are BCMA-directed CAR-T cell therapies that have been compared to standard of care (SOC) regimens for MM in early relapse in the phase III trials KarMMa-3 and CARTITUDE-4, respectively. Both studies demonstrated a significantly improved in response rates, depth of response, and progression-free survival compared to SOC. BsAbs teclistamab and elranatamab have been evaluated in the phase II trials MajesTEC-1 and MagnetisMM-3, respectively. Overall response rates of 63 and 61% were observed with teclistamab and elranatamab, respectively, in a population of patients with heavily pretreated RRMM. Relevance to Patient Care and Clinical Practice in Comparison with Existing Drugs: BCMA-directed immunotherapies have demonstrated efficacy in the treatment of RRMM. Safety issues with BCMA-directed immunotherapies include cytokine release syndrome, neurotoxicity, infections, and cytopenias. Operational challenges and issues with access to care exist with these therapies as they may be limited to institutions with the infrastructure to safely administer and monitor patients for toxicities.

Conclusion

BCMA-directed immunotherapies represent an important advancement in the management of RRMM and have significantly added to the available treatment options for this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaB-Cell Maturation AntigenImmunotherapyHumansImmunotherapy, AdoptiveAntibodies, BispecificReceptors, Chimeric Antigen

Stichwörter der Autor:innen

B-cell maturation antigenCAR-T cell therapybispecific antibodiesimmunotherapymultiple myeloma

Substanzen

B-Cell Maturation AntigenAntibodies, BispecificReceptors, Chimeric Antigenidecabtagene vicleucelTNFRSF17 protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, Virginia Commonwealth University Medical Center, VCU Health, Richmond, VA, USA.
  • Division of Pharmacy, Atrium Health Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

ORCID-Profile: Donald C Moore

Zitieren

APA

Peery, M. R., Hill, H., Sharps, A., Zaver, A., & Moore, D. C. (2025). B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280241282115

Vancouver

Peery MR, Hill H, Sharps A, Zaver A, Moore DC. B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280241282115

BibTeX
@article{Peery2025,
  author = {Peery, Matthew R and Hill, Hailey and Sharps, Amanda and Zaver, Aarti and Moore, Donald C},
  title = {B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice},
  journal = {Annals of Pharmacotherapy},
  year = {2025},
  doi = {10.1177/10600280241282115}
}
Kostenlos starten →